Form 4: Denali CEO Sells Shares for Tax Obligations

Denali Therapeutics Inc. CEO Ryan J. Watts sold 35,198 shares of common stock at $16.5 per share to cover tax obligations related to vested restricted stock units.

Summary

• Ryan J. Watts, President and CEO, and a Director of Denali Therapeutics Inc. (DNLI), reported a transaction involving the company's common stock.
• On January 6, 2026, Watts disposed of 35,198 shares of common stock at a price of $16.5 per share.
• The sale was conducted to satisfy tax obligations incurred by Watts in connection with the settlement of previously vested Restricted Stock Units (RSUs).
• This transaction was made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following the reported transaction, Watts directly beneficially owns 296,833 shares of common stock, which includes 184,915 unvested RSUs.
• Additionally, Watts indirectly beneficially owns 2,152,604 shares of common stock through the Watts Family 2015 Trust, for which he serves as trustee.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale to cover tax obligations from vested equity, which is a neutral event and does not reflect positively or negatively on the company's operational or financial performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing represents a routine insider transaction for a publicly traded biotechnology company. Sales to cover tax obligations related to equity compensation are common and generally not indicative of a change in management's view of the company's prospects.

Related Party Transactions

• Ryan J. Watts indirectly holds 2,152,604 shares through the Watts Family 2015 Trust, for which he serves as trustee.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, tax-related sale by an insider, not indicative of a change in company fundamentals or management confidence.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned sale of shares by the CEO to cover tax liabilities associated with vested restricted stock units. Such transactions are not typically indicative of a change in management's confidence in the company's future prospects and do not provide new information to alter an investment thesis. Therefore, a 'hold' recommendation is appropriate.

Keywords

Denali Therapeutics, DNLI, Insider Trading, Form 4, Ryan J. Watts, CEO, Stock Sale, Tax Obligations, RSUs, Rule 10b5-1